Insulin degludec/liraglutide - Novo Nordisk
Alternative Names: IDegLira; Insulin degludec/Victoza; Liraglutide/insulin degludec; Liraglutide/NN 1250; Liraglutide/Tresiba; NN 1250/liraglutide; NN-9068; Tresiba/liraglutide; Victoza/insulin degludec; XultophyLatest Information Update: 05 Nov 2023
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
- Mechanism of Action Glucagon receptor antagonists; Glucagon-like peptide-1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 29 Mar 2023 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Hong Kong, China (SC)
- 08 Jul 2022 Novo Nordisk completes a phase III IDegLira HIGH trial in Type 2 diabetes mellitus in USA (SC) (NCT03737240)
- 27 Nov 2020 Launched for Type 2 diabetes mellitus in Italy (SC), prior to November 2020